A Unique “Composite” PTLD with Diffuse Large B-Cell and T/Anaplastic Large Cell Lymphoma Components Occurring 17 Years after Transplant [PDF]
Case Reports in Hematology, 2013 Posttransplant lymphoproliferative disorder (PTLD) comprises a spectrum ranging from polyclonal hyperplasia to aggressive monoclonal lymphomas. The majority of PTLDs are of B-cell origin while T-cell PTLDs and Hodgkin lymphoma-like PTLDs are uncommon ...
Kristin La Fortune +3 more
doaj +2 more sources
HLA and pathogens in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and other post-infection conditions [PDF]
Scientific ReportsViral infections have been widely implicated in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) pathogenesis. Recent evidence has also identified certain Human Leukocyte Antigen (HLA) alleles that are significantly associated with ME/CFS risk/
Apostolos P. Georgopoulos +2 more
doaj +2 more sources
The IPTA Nashville Consensus Conference on Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation in Children: Updates on Classification and Prevention-2026. [PDF]
Pediatr TransplantABSTRACT The 2019 International Pediatric Transplant Association (IPTA) consensus conference assessed available evidence and developed recommendations for various aspects of care relating to post‐transplant lymphoproliferative disorders (PTLD) after solid organ transplantation in children.
Green M +7 more
europepmc +2 more sources
Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes [PDF]
Frontiers in ImmunologyIntroductionOncohematological disorders are heterogeneous conditions that present significant challenges in management prior to transplantation. Data about rejection risk, disease recurrence, eligibility criteria, and requested remission time before ...
Alberto Mella +32 more
doaj +2 more sources
The Caregiver’s Experience of Post-Treatment Lyme Disease Syndrome [PDF]
, 2022 As the rate of Lyme disease diagnoses increases in the United States, it can be assumed that the frequency at which post-treatment Lyme disease syndrome (PTLDS) is diagnosed will also increase.
Deschene, Jordyn
core +2 more sources
Treatment of PTLD with Rituximab or Chemotherapy [PDF]
American Journal of Transplantation, 2006 Information regarding treatment of post-transplant lymphoproliferative disease (PTLD) beyond reduction in immunosuppression (RI) is limited. We retrospectively evaluated patients receiving rituximab and/or chemotherapy for PTLD for response, time to treatment failure (TTF) and overall survival (OS). Thirty-five patients met inclusion criteria.
R L, Elstrom +10 more
openaire +2 more sources
PLoS ONE, 2021 BackgroundPersistent symptoms attributed to presumed tick-bite exposure constitute an unresolved medical controversy. We evaluated whether Swedish adults who met the criteria for post-treatment Lyme disease syndrome (PTLDS) exhibited characteristics ...
Kenneth Nilsson +8 more
doaj +1 more source
Fitoterapia zespołu poboreliozowego
Herbalism, 2021 Uznanym standardem leczenia boreliozy jest antybiotykoterapia, zarówno w monoterapii, jak i łączona. We wczesnej fazie choroby wykazują one umiarkowaną skuteczność.
Przemysław Figura
doaj +1 more source
Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome
, 2021 BACKGROUND: Post-treatment Lyme disease symptoms/syndrome (PTLDS) occurs in approximately 10% of patients with Lyme disease following antibiotic treatment.
Delorey, Mark J +10 more
core +1 more source
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018 Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of transplantation, which represent a heterogeneous group of lymphoproliferative diseases and show a spectrum of clinical, morphologic, and molecular genetic features ranging from reactive polyclonal lesions to frank lymphomas.
openaire +2 more sources